Literature DB >> 11341236

Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart.

N Paolocci1, R Biondi, M Bettini, C I Lee, C O Berlowitz, R Rossi, Y Xia, G Ambrosio, A L'Abbate, D A Kass, J L Zweier.   

Abstract

Oxygen free radicals (OFR) play a primary role in ischemia-reperfusion-mediated vascular dysfunction and this is paralleled by a loss of endothelial nitric oxide synthase (eNOS) activity. The authors tested whether a direct exposure to OFR may affect vascular relaxation by altering nitric oxide (NO) release. Effects of electrolysis(EL)-generated OFR on basal and agonist-evoked NO release were monitored in isolated rat hearts by oxyhemoglobin assay. Electrolysis-induced changes were compared with those obtained after 30 min perfusion with NOS and cyclooxygenase (COX) inhibitors NG-nitro-L-arginine methyl ester (L-NAME, 100 microM) and indomethacin (INDO, 1 m M). Electrolysis-generated hydroxyl radical (.OH) formed by.O2-and H2O2 via the Fenton reaction as revealed by Electron Paramagnetic Resonance (EPR). After EL, basal NO release declined by 60% and coronary perfusion pressure (CPP) increased by approximately 70%. L-NAME/INDO perfusion similarly lowered NO release (-63%) but increased CPP less than EL (56+/-3%P<0.03 v post-EL). In presence of excess substrates and cofactors eNOS activity was not affected by EL. Both acetylcholine (ACh; 1 microM) and bradykinin (BK; 10 n M) had minimal effect in reversing EL-induced vasoconstriction, whereas both partially reversed L -NAME/INDO-mediated constriction. Sodium nitroprusside (SNP, 1 microM) completely reversed L-NAME/INDO constriction and partly countered that after EL (-38+/-2.5, P<0.001). Acetylcholine-evoked NO release was nearly abolished by both treatments whereas BK still elicited partial NO release after eNOS/cyclooxygenase inhibition (P<0.001) but not after EL. In conclusion, OFR severely impair NO-mediated coronary vasorelaxation affecting both basal and agonist-evoked NO release but not eNOS activity. However, EL also significantly blunts NOS/COX-independent vasodilation suggesting alteration of other vasodilatative pathways. Copyright 2001 Academic Press

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341236     DOI: 10.1006/jmcc.2000.1334

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  40 in total

Review 1.  GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  Cell Signal       Date:  2017-01-07       Impact factor: 4.315

2.  Vasoactive actions of nitroxyl (HNO) are preserved in resistance arteries in diabetes.

Authors:  Marianne Tare; Rushita S R Kalidindi; Kristen J Bubb; Helena C Parkington; Wee-Ming Boon; Xiang Li; Christopher G Sobey; Grant R Drummond; Rebecca H Ritchie; Barbara K Kemp-Harper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-10       Impact factor: 3.000

3.  Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.

Authors:  Fadi N Salloum; Anindita Das; Arun Samidurai; Nicholas N Hoke; Vinh Q Chau; Ramzi A Ockaili; Johannes-Peter Stasch; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-20       Impact factor: 4.733

Review 4.  Nitric oxide signalling in cardiovascular health and disease.

Authors:  Charlotte Farah; Lauriane Y M Michel; Jean-Luc Balligand
Journal:  Nat Rev Cardiol       Date:  2018-02-01       Impact factor: 32.419

5.  Animal model of left atrial thrombus in congestive heart failure in rats.

Authors:  Jiqiu Chen; Benjamin Strauss; Lifan Liang; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-10       Impact factor: 4.733

6.  Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis.

Authors:  Konstantinos Papoutsis; Alkistis Kapelouzou; Diamantis I Tsilimigras; Nikolaos Patelis; Georgios Kouvelos; Dimitrios Schizas; Ioannis Karavokyros; Sotirios Georgopoulos
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

7.  Protein kinase CbetaII-mediated phosphorylation of endothelial nitric oxide synthase threonine 495 mediates the endothelial dysfunction induced by FK506 (tacrolimus).

Authors:  Valorie L Chiasson; Matthew A Quinn; Kristina J Young; Brett M Mitchell
Journal:  J Pharmacol Exp Ther       Date:  2011-03-07       Impact factor: 4.030

8.  Investigation of bioactive NO-scavenging role of myoglobin in myocardium.

Authors:  Ulrike Kreutzer; Thomas Jue
Journal:  Pflugers Arch       Date:  2006-02-09       Impact factor: 3.657

9.  Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation.

Authors:  Barbara K Kemp-Harper; Anida Velagic; Nazareno Paolocci; John D Horowitz; Rebecca H Ritchie
Journal:  Handb Exp Pharmacol       Date:  2021

10.  Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.

Authors:  Nikolaos Tzemos; Pitt O Lim; Thomas M MacDonald
Journal:  Cardiovasc Ther       Date:  2009-07-14       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.